New England Journal of Medicine· 2015Q1

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, Darrell White et al.

1,328citations
Q1SCImago
2015year

Short summary

Adding elotuzumab to lenalidomide and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma, extending median PFS by 4.5 months (19.4 vs. 14.9 months) and reducing the risk of progression or death by 30%.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine